Cross-linked hyaluronzuur - Wat u moet weten over deze innovatieve behandeling

A CLOSER LOOK AT THE HYDRA HYALURONIC ACID TREATMENT COLLECTION

The HYDRA facial skincare collection was launched in 2022 and is formulated using hyaluronic acids of different molecular weights. The HYDRA treatments draw their inspiration from injections used in aesthetic medicine and are suitable for all skin types, including sensitive skin.

The collection consists of three exceptional skincare treatments :

- HYDRA-HYAL SERUM is the collection's cornerstone. It's applied directly after cleansing your skin . Its formula combines the five different types of hyaluronic acid we looked at above with an antioxidant-rich extract of the Japanese pagoda tree. The result is immediate plumping and 24-hour moisturization*, while also providing optimal protection against external stresses.

- To complement the serum, our HYDRA-HYAL CREAM also contains the five different types of hyaluronic acid to provide intense moisturization for normal to dry skin.

- People with oily skin can replace this moisturizer with our HYDRA-HYAL CREAM-GEL, which is our mattifying anti-aging face cream. Enriched with mastic extract, which has astringent properties, this hydrating face cream tightens pores, smooths out imperfections, and gives the complexion a lasting matte finish.

Find out more about all of the products in the HYDRA collection.

*Clinical study - 20 volunteers - after a single application of the HYDRA-HYAL SERUM.

Results

Demographic data and functional scores of 30 patients from both injection groups who met the inclusion and exclusion criteria and completed their treatment with six-month functional follow-up are shown in Table I.

Table 1

According to Mauchly’s test, the assumption of sphericity was not met since p

Patients and Methods

This single-center, retrospective study was conducted at the Kütahya Health Sciences University Hospital, Department of Orthopedics and Traumatology between February 2020 and February 2022. The study sample consisted of 60 OA patients (47 females, 13 males, mean age: 57.9±4.3 years, range, 50 to 65 years). Data of the patients were retrieved from the medical records in the hospital database, and no additional interventional procedures were performed. The inclusion criteria were as follows: patients who underwent either type of HA injection (linear or cross-linked HA, the decision of which injection type to apply was left to the patient), age >50 years, knee scores obtained before injection and at three and six months after injection, patients with Kellgren-Lawrence Grade 2 or 3 gonarthrosis, being followed in our center, patients who have been followed for at least six months, patients who had previously received conservative treatment and whose treatment was unsuccessful. The exclusion criteria were as follows: patients with missing data, age 30, knee alignment varus >15º or valgus >15º, patients with active infection, cancer, and peripheral neuropathy.

Patients were randomly divided into two intra-articular knee injection treatment regimen groups with 30 participants in each group: those who underwent intra-articular injections of cross-linked HA (single dose) and those who received intra-articular injections of linear HA (three doses, once a week). A comparison of the functional outcomes was conducted resulting from two distinct injections: a 2 mL dose of 2.4% 48 mg cross-linked HA (SO Visc Cross-Linked, Biolot Medical, Ankara, Türkiye) and a 2 mL dose of 2.4% 48 mg linear HA (SO Visc, Biolot Medical, Ankara, Türkiye) knee injection. The molecular weight distribution of sodium hyaluronate in standard HA injections is 1.6 to 2.4 million daltons. Moreover, it does not contain HA fragments lower than 500,000 daltons. In cross-linked HA injections, the molecular weight distribution of cross-linked HA is between 5 to 6 million daltons.